Adumb, I assume? He is totally clueless about the massive market for the PA franchise, guess Krammer is telling him to bash POZN for his butt buddies. Didn't like the news from the CC that AZn is giving up on Vivimo though:
"On May 3, 2013, AstraZeneca informed POZEN that it will focus its future promotional efforts for VIMOVO in specific markets where AstraZeneca feels sufficient future potential can be realized. By the end of third quarter of this year, AstraZeneca will continue to make available, but plans to cease promotion of VIMOVO in certain countries, including the U.S. and in Europe, with the exception of Spain and Portugal, due to existing contractual arrangements with third parties. For the remaining countries where VIMOVO is on the market, which accounted for 47% of sales in Q1, promotion will continue. Decisions to launch in new countries will be made by AstraZeneca on a case-by-case basis. We are unsure, at this point, of the impact on our future revenue from this change in strategy, however, we will update investors when we have greater clarity. "
But if they can keep the burn rate around $7M per Q while waiting on the FDA decision on PA's, with $80M in the bank they should have plenty of money to keep the lights on.